Literature DB >> 20447656

Induction of heart failure by minimally invasive aortic constriction in mice: reduced peroxisome proliferator-activated receptor γ coactivator levels and mitochondrial dysfunction.

Gloria Faerber1, Frederico Barreto-Perreia, Maria Schoepe, Ralf Gilsbach, Andrea Schrepper, Michael Schwarzer, Friedrich W Mohr, Lutz Hein, Torsten Doenst.   

Abstract

OBJECTIVE: Mitochondrial dysfunction has been suggested as a potential cause for heart failure. Pressure overload is a common cause for heart failure. However, implementing pressure overload in mice is considered a model for compensated hypertrophy but not for heart failure. We assessed the suitability of minimally invasive transverse aortic constriction to induce heart failure in C57BL/6 mice and assessed mitochondrial biogenesis and function.
METHODS: Minimally invasive transverse aortic constriction was performed through a ministernotomy without intubation (minimally invasive transverse aortic constriction, n = 68; sham operation, n = 43). Hypertrophy was assessed based on heart weight/body weight ratios and histologic analyses, and contractile function was assessed based on intracardiac Millar pressure measurements. Expression of selected metabolic genes was assessed with reverse transcription-polymerase chain reaction and Western blotting. Maximal respiratory capacity (state 3) of isolated mitochondria was measured with a Clark-type electrode.
RESULTS: Survival was 62%. Within 7 weeks, minimally invasive transverse aortic constriction induced significant hypertrophy (heart weight/body weight ratio: 10.08±0.28 mg/g for minimally invasive transverse aortic constriction vs 4.66±0.07 mg/g for sham operation; n=68; P<.01). Fifty-seven percent of mice undergoing minimally invasive transverse aortic constriction displayed signs of heart failure (pleural effusions, dyspnea, weight loss, and dp/dtmax of 3114±422 mm Hg/s, P<.05). All of them had heart weight/body weight ratios of greater than 10. Mice undergoing minimally invasive transverse aortic constriction with heart weight/body weight ratios of less than 10 had normal contractile function (dp/dtmax of 6471±292 mm Hg/s vs dp/dtmax of 6933±205 mmHg/s in sham mice) and no clinical signs of heart failure. The mitochondrial coactivator peroxisome proliferator-activated receptor γ coactivator alpha (PGC-1α) was downregulated in failing hearts only. PGC-1α and fatty acid oxidation gene expression were also decreased in failing hearts. State 3 respiration of isolated mitochondria was significantly reduced in all hearts subjected to pressure overload.
CONCLUSIONS: Contractile dysfunction and heart failure can be induced in wild-type mice by means of minimally invasive aortic constriction. Pressure overload-induced heart failure in mice is associated with mitochondrial dysfunction, as characterized by downregulation of PGC-1α and reduced oxidative capacity. Copyright Â
© 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447656     DOI: 10.1016/j.jtcvs.2010.03.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

Review 1.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

2.  Hydrogen sulfide regulates cardiac mitochondrial biogenesis via the activation of AMPK.

Authors:  Yuuki Shimizu; Rohini Polavarapu; Kattri-Liis Eskla; Chad K Nicholson; Christopher A Koczor; Rui Wang; William Lewis; Sruti Shiva; David J Lefer; John W Calvert
Journal:  J Mol Cell Cardiol       Date:  2018-02-03       Impact factor: 5.000

Review 3.  A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.

Authors:  Ashish Gupta; Brian Houston
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

4.  Docosahexaenoic acid supplementation alters key properties of cardiac mitochondria and modestly attenuates development of left ventricular dysfunction in pressure overload-induced heart failure.

Authors:  Erinne R Dabkowski; Kelly A O'Connell; Wenhong Xu; Rogerio F Ribeiro; Peter A Hecker; Kadambari Chandra Shekar; Caroline Daneault; Christine Des Rosiers; William C Stanley
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

5.  Variable phenotype in murine transverse aortic constriction.

Authors:  Selma F Mohammed; Jimmy R Storlie; Elise A Oehler; Lorna A Bowen; Josef Korinek; Carolyn S P Lam; Robert D Simari; John C Burnett; Margaret M Redfield
Journal:  Cardiovasc Pathol       Date:  2011-07-18       Impact factor: 2.185

6.  Minimally Invasive Transverse Aortic Constriction in Mice.

Authors:  Aung Moe Zaw; Connor M Williams; Helen K W Law; Billy Kwok Chong Chow
Journal:  J Vis Exp       Date:  2017-03-14       Impact factor: 1.355

7.  Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post-myocardial infarction cardiomyopathy: benefits of Alda-1.

Authors:  Katia M S Gomes; Luiz R G Bechara; Vanessa M Lima; Márcio A C Ribeiro; Juliane C Campos; Paulo M Dourado; Alicia J Kowaltowski; Daria Mochly-Rosen; Julio C B Ferreira
Journal:  Int J Cardiol       Date:  2014-10-23       Impact factor: 4.164

Review 8.  Mitochondria as a therapeutic target in heart failure.

Authors:  Marina Bayeva; Mihai Gheorghiade; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

9.  Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy.

Authors:  Reza Tavakoli; Simona Nemska; Peiman Jamshidi; Max Gassmann; Nelly Frossard
Journal:  J Vis Exp       Date:  2017-09-25       Impact factor: 1.355

Review 10.  Mitochondrial quality control mechanisms as molecular targets in cardiac ageing.

Authors:  Anna Picca; Robert T Mankowski; Jonathon L Burman; Luca Donisi; Jae-Sung Kim; Emanuele Marzetti; Christiaan Leeuwenburgh
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.